RT Journal Article
SR Electronic
T1 Antagonistic Modulation Between the <em>Delta</em> Opioid Agonist BW373U86 and the <em>Mu</em> Opioid Agonist Fentanyl in Mice
JF Journal of Pharmacology and Experimental Therapeutics
JO J Pharmacol Exp Ther
FD American Society for Pharmacology and Experimental Therapeutics
SP 271
OP 277
VO 282
IS 1
A1 Scott J. O’Neill
A1 Mark A. Collins
A1 Hugh O. Pettit
A1 Robert W. McNutt
A1 Kwen-Jen Chang
YR 1997
UL http://jpet.aspetjournals.org/content/282/1/271.abstract
AB This study was performed to assess the interactions that occur betweendelta-and mu opioid receptors by studying effects of the systemically active nonpeptide deltaagonist BW373U86 and the mu agonist fentanyl in mice. Concentrations of the compounds were varied, and analgesic responses were determined by 55°C hot-plate assays. BW373U86 produced hot-plate antinociceptive activity along with convulsive side effects. These effects could be antagonized by the selective deltaantagonist naltrindole. Fentanyl produced hot-plate antinociceptive activity with Straub tail and hyperactivity as side effects. When BW373U86 and fentanyl were coadministered, BW373U86 convulsive activity was attenuated by fentanyl in a dose-dependent manner and the fentanyl-induced Straub tail effect was antagonized by BW373U86, also in a dose-dependent manner. Hot-plate analgesic activity was additive between the two compounds. The delta antagonist naltrindole partially antagonized the ability of BW373U86 to block the fentanyl-induced Straub tail effect. The mu antagonist β- funaltrexamine antagonized the fentanyl-induced blockade of the convulsive effects of BW373U86. These data suggest that complex inhibitory interactions take place between mu anddelta receptors in mice. Future studies are clearly needed to study the neuromodulatory effects of mu anddelta receptors. The widespread use of muagonists in the clinic indicates that a large number of patients exist who could greatly benefit from the conjunctive use ofdelta pharmaceuticals. The American Society for Pharmacology and Experimental Therapeutics